Biotech | November 20, 2021
Oravax and Genomma JV to commercialise Covid-19 vaccine in Mexico and Latam
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
The vaccine will be manufactured and marketed in the Philippines by SII under the brand name Covovax
Diabetes has the highest prevalence and comorbidities among all NCD’s in India and it is mostly found among people in the south and east India
The European Commission (EC) granted marketing authorisation for Celltrion’s regdanvimab following a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) last week
Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus
The company expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Evidence also shows better immune response to virus among users of spray
Subscribe To Our Newsletter & Stay Updated
